Technology/Product: Patented Chimeric Antigen Receptor T-cell therapy (CAR-T) and explore its potential to cure cancer and provide affordable cancer treatment.
Fostered at: SINE, IIT Bombay
ImmunoACT researchers used gene and cell therapies to re-engineer immune cells and attack cancer cells in the body to kill them off. The treatment procedure is also less painful than chemotherapy, surgery, and other forms of cancer treatment and was also known to reduce the chances of a relapse.
The founders are committed to bringing CAR-T cell therapy to Indian patients at an affordable cost. The treatment which is currently available in high-end private hospitals in the US would cost around Rs. 3-4 crores. Their latest breakthrough came in June 2020, wherein a first-in-human phase-I/II clinical trial has officially approved to begin, thanks to financial support from the Biotechnology Industry Research Assistance Council (BIRAC) worth Rs. 18.96 Crores. In 2021, Prof Rahul and his team have achieved the one-of-its-kind feat by successfully conducting clinical trials for the first indigenously developed CAR T-cell therapy for blood cancer treatment along with Tata Memorial Centre.
This start-up has been fostered at Society for Innovation and Entrepreneurship (SINE), IIT Bombay. SINE is an umbrella organisation at IIT Bombay for fostering entrepreneurship and nurturing tech start-ups. It is a business incubator which provides ‘Start to scale’ support for technology-based entrepreneurship and facilitates the conversion of research activity into entrepreneurial ventures